CA
NZ
UK
AU
IND
US
Sickle Cell Disease: The Pyruvate Kinase Connection
The GLP-1 Adherence Crisis That NanoPortal Addresses
The Gene Therapy Financing Innovation
What the Priority Review Voucher Means in Practice
The GCC Fertility Market Opportunity
Alcohol Use Disorder: The Treatment Gap That MEAI Targets
Why Vertex Is Diversifying Beyond Cystic Fibrosis
PALSONIFY: A Commercial Anchor With First-Mover Advantages
Treatment-Resistant Depression: The Scale of Unmet Need
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares moved sharply higher in trading today after the FDA granted Priority Review to the company's supplemental New Drug Application for mitapivat in sickle cell disease. Agios is a Cambridge, Massachusetts-based commercial-stage biopharmaceutical company focused on rare disease treatments, with …
Please wait processing your request...